MOA

MAVENCLAD™ PREDOMINATELY AFFECTS LYMPHOCYTES WHILE CELLS OF THE INNATE IMMUNE SYSTEM ARE LESS AFFECTED^1*†

MS pathology involves a complex chain of events in which different immune cell types, including autoreactive T and B cells, play a key role. While MAVENCLAD’s mechanism of action is not fully understood, its predominant effect on lymphocytes is thought to interrupt the cascade of immune events central to MS.

Cells of the innate immune system are less affected than cells of the adaptive immune system

MAVENCLAD has an estimated terminal half-life of 23h^‡  

* Clinical significance is unknown.

† MAVENCLAD’s predominant effect on lymphocytes may be explained by variations in the expression levels of deoxycytidine kinase (DCK) and 5'-nucleotidase (5'-NTase) between immune cell subtypes.

‡ Based on pooled population pharmacokinetic data. Drug accumulation does not occur after once daily dosing as this half-life only accounts for a small portion of the AUC.